Plus Therapeutics, Inc. Stock News

AUSTIN, Texas, April 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized the

The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 40% pre-market. This is why it happened.

Agreement covers intermediate drug product for RNL™, a radiotherapy in development for several rare cancer targets Agreement covers intermediate drug product for RNL™, a radiotherapy in developmen

AUSTIN, Texas, March 03, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q4 2020 Results - Earnings Call Transcript

– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized ther

AUSTIN, Texas, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therap

AUSTIN, Texas, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ann

AUSTIN, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- P lus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized thera

AUSTIN, Texas, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage company focused on making a positive impact on patients' lives, today ann

AUSTIN, Texas., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:  PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized the

Investigational drug RNL ™ d eliver s u p to fifteen t imes the a bsorbed d ose of r adiation c ompared to standard e xternal b eam r adiation t herapy

Company Management and Principal Investigator of ReSPECT to Discuss Interim Data

Data and Safety Monitoring Board evaluated safety data in recommending cohort progression Data and Safety Monitoring Board evaluated safety data in recommending cohort progression